Superconducting and normal properties of the set of Mo/Si superlattices with variable Si layer thickness

We report the results of the superconducting and kinetic parameter measurements (transition temperature Tc, parallel and perpendicular critical fields Hc₂, resistivity in the normal state) on a set of Mo/Si superconducting superlattices with a constant metal layer thickness dₘₒ=22 A and variable semiconducting one dₛᵢ(14-44 A ). Our data show a monotonic dependence of all measured parameters on dₛᵢ. It is found that the Josephson interlayer coupling energy depends exponentially on the spacer thickness. The data obtained allowed us to determine the characteristic electron tunneling length for amorphous silicon with high precision. It is equal to 3.9 A. Enhancement of interlayer coupling leads to the Mo/Si multilayer transition temperature increasing, in agreement with Horovitz theory and with the experimental data on high-Tc materials

RESULTS OF THE PHARMACOECONOMIC ANALYSIS OF THE USE OF A PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE FOR PREVENTION OF PNEUMOCOCCAL INFECTIONS IN CHILDREN DURING FIRST 5 YEARS OF LIFE IN THE RUSSIAN FEDERATION

The article discusses the first results of a pharmacoeconomic analysis of the efficacy of using the Pneumococcal conjugated 7-valent vaccine (PCV7) for immunization of children aged 2 months to 5 years in Russia using techniques for modeling various approaches to cohort immunization. It shows clinical and economic efficacy of implementing routine immunization in children during first 5 years against pneumococcal infection using PCV7 given direct and indirect costs. It justifies the expediency of incorporating vaccination against pneumococcal infection in children aged 2 months up into the Russian National Immunization Schedule.Key words: pharmacoeconomic analysis, children during first 5 years of life, vaccination, pneumococcal conjugated 7-valent vaccin

RESULTS OF THE PHARMACOECONOMIC ANALYSIS OF THE USE OF A PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE FOR PREVENTION OF PNEUMOCOCCAL INFECTIONS IN CHILDREN DURING FIRST 5 YEARS OF LIFE IN THE RUSSIAN FEDERATION

The article discusses the first results of a pharmacoeconomic analysis of the efficacy of using the Pneumococcal conjugated 7-valent vaccine (PCV7) for immunization of children aged 2 months to 5 years in Russia using techniques for modeling various approaches to cohort immunization. It shows clinical and economic efficacy of implementing routine immunization in children during first 5 years against pneumococcal infection using PCV7 given direct and indirect costs. It justifies the expediency of incorporating vaccination against pneumococcal infection in children aged 2 months up into the Russian National Immunization Schedule.Key words: pharmacoeconomic analysis, children during first 5 years of life, vaccination, pneumococcal conjugated 7-valent vaccin

РЕЗУЛЬТАТЫ ФАРМАКОЭКОНОМИЧЕСКОГО АНАЛИЗА ПРИМЕНЕНИЯ ПНЕВМОКОККОВОЙ КОНЪЮГИРОВАННОЙ 7-ВАЛЕНТНОЙ ВАКЦИНЫ ДЛЯ ПРОФИЛАКТИКИ ПНЕВМОКОККОВЫХ ИНФЕКЦИЙ У ДЕТЕЙ ПЕРВЫХ 5 ЛЕТ ЖИЗНИ В РОССИЙСКОЙ ФЕДЕРАЦИИ

The article discusses the first results of a pharmacoeconomic analysis of the efficacy of using the Pneumococcal conjugated 7-valent vaccine (PCV7) for immunization of children aged 2 months to 5 years in Russia using techniques for modeling various approaches to cohort immunization. It shows clinical and economic efficacy of implementing routine immunization in children during first 5 years against pneumococcal infection using PCV7 given direct and indirect costs. It justifies the expediency of incorporating vaccination against pneumococcal infection in children aged 2 months up into the Russian National Immunization Schedule.Key words: pharmacoeconomic analysis, children during first 5 years of life, vaccination, pneumococcal conjugated 7-valent vaccineВ статье приведены первые результаты фармакоэкономического анализа эффективности применения пневмококковой конъюгированной 7-валентной вакцины (ПКВ7) для иммунизации детей в возрасте от 2 мес до 5 лет в России с использованием методов моделирования различных подходов к когортной иммунизации. Показана клинико-экономическая эффективность внедрения рутинной иммунизации детей первых 5 лет жизни против пневмококковой инфекции с использованием ПКВ7 с учетом прямых и непрямых затрат. Обоснована целесообразность включения вакцинации против пневмококковой инфекции детей с возраста 2 мес в Российский национальный календарь иммунизации.Ключевые слова: фармакоэкономический анализ, вакцинация, пневмококковая конъюгированная 7-валетная вакцина, Национальный календарь иммунизации России. (Педиатрическая фармакология. – 2009;6(6): 6-10